Are we getting closer to apply AI-based techniques in clinical practice?
AI technology is being tested across tumour types and with different purposes, with an emerging trend for adding value to whole slide image analyses for HER2 status
Pathogenic variants in HRR genes can be a risk factor for anthracycline-induced cardiotoxicity
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available
Building a lasting foundation for precision oncology
While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients.
Can telehealth be a genuine replacement for face-to-face healthcare?
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
Practice-changing treatments in GU cancers continue to evolve
Finding the best treatment strategy for patient subpopulations and adequate funding are key to further advancing the field, says ESMO Award 2022 recipient Prof. Karim Fizazi
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
More needs to be done in renal cancer
Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier
Enhanced patient participation in trials may help make cancer research more heterogeneous
In the Patient Advocacy Track, the importance and challenges around placing the patient at the centre of clinical trials
Cancer Research
Colorectal cancer: guided by the gut?
Recent evidence suggests a role of the microbiome in cancer pathogenesis and as a potential therapeutic target, but it is still early days
Can academic oncology compete with the career prospects offered by the pharma industry?
Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities